Hints and tips:
Related Special Reports
Related Topics
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...Roche said it was also reviewing its manufacturing operations to improve efficiency. It recently sold a large site in California to contract manufacturer Lonza for $1.2bn....
...Roche sales fell by 6 per cent in the first quarter of 2024 due to the strong Swiss franc and falling sales of its Covid-19 treatment Ronapreve....
...But the franc’s gain of more than 10 per cent against the US dollar in 2023 hit Roche, which makes many of its sales in the US....
...It is the second bolt-on acquisition by Roche’s new chief executive Thomas Schinecker in less than two months. Schinecker needs to soothe investor jitters over Roche’s pipeline....
...Roche is to acquire Carmot Therapeutics for up to $3.1bn, in the industry’s latest significant investment in the booming obesity treatment market....
...Roche, whose stock has fallen 27 per cent in the past 12 months, is a case in point....
...Roche shares closed up almost 3 per cent on Monday, but remain down 15 per cent this year....
...Thomas Schinecker, who took over as Roche chief executive in March, said the drug has “transformational potential”. Roche will pay $7.1bn upfront and a near term milestone payment of $150mn....
...Roche will pay $7.1bn upfront and a near-term milestone payment of $150mn. Pfizer will keep the commercialisation rights outside the US and Japan....
...Roche is therefore acquiring US-based obesity drugs developer Carmot for up to $3.1bn. The Swiss company already has a packed pipeline. The problem is that too many drug trials have failed....
...Roche, Johnson & Johnson and Denmark’s Genmab have all inked deals this year, following nearly $100bn of ADC-focused M&A and partnership transactions last year....
...Shares in Roche increased 5.1 per cent to SFr265.95....
...Roche is struggling to convince investors that it can boost its research productivity after high profile setbacks in 2022....
...Consider how Roche spent its cash. It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...Roche is conducting phase 1 clinical trials in humans on the candidate drug, which targets a bacterium known as carbapenem-resistant Acinetobacter baumannii, or CRAB....
...In fact, Roche has had the biggest negative impact of any single stock on the Stoxx 600 since the start of last year. . . make of that what you will....
...Earnings: Oil major Shell, beverage maker AG Barr and air carrier Icelandair will report, as will casino operator Rank Group and biopharma companies Novozymes, Roche and Sanofi....
...That in turn has prompted a rash of dealmaking, with Roche, J&J and Genmab all sealing acquisitions this year following a bumper period for M&A and partnerships last year....
...The former Roche pharmaceuticals boss took on one of the most unenviable jobs in corporate Europe last June....
...Ubben disclosed a 0.83 per cent stake in Bayer a year ago, becoming a leading force behind the ousting of then chief executive Werner Baumann, who was replaced by Bill Anderson, a former Roche manager....
...A former Roche manager who joined the German group last year, Anderson said he acknowledged the appeal of a “pure play structure” of pharma, crop science and over-the-counter consumer drugs....
...AstraZeneca has signed a licensing agreement with Chinese company Eccogene, which is developing a weight-loss pill, while Swiss pharma group Roche bought obesity drug developer Carmot Therapeutics for $2.7bn...
...Companies including UK’s AstraZeneca and Swiss group Roche have recently acquired or licensed weight-loss drugs in an effort to enter a market that analysts expected would exceed $100bn by 2030....
International Edition